Crossmark

Phase 2 study of everolimus for relapsed or refractory classical Hodgkin lymphoma

Published Online: 2018-05-11

Published Print: 2018-12

Authors

Johnston, Patrick B.

Pinter-Brown, Lauren C.

Warsi, Ghulam

White, Kristen

Ramchandren, Radhakrishnan
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct01022996 at ClinicalTrials.gov

Documents that mention this clinical trial

Phase 2 study of everolimus for relapsed or refractory classical Hodgkin lymphoma
https://doi.org/10.1186/s40164-018-0103-z
Funding

Funding for this research was provided by:

Novartis Pharmaceuticals Corporation
License Information

Text and Data Mining valid from 2018-05-11

Version of Record valid from 2018-05-11
More Information

Article History

Received: 30 January 2018

Accepted: 24 April 2018

First Online: 11 May 2018

Document is current